A major milestone for cancer diagnostics: Precision Epigenomics earns Fast Lane recognition for its innovation in molecular diagnostics and cancer detection.
Innovation in healthcare begins with groundbreaking research, dedicated collaboration, and a shared commitment to making a difference. For Precision Epigenomics, these principles continue to drive progress in the field of cancer diagnostics.
Precision Epigenomics is proud to be recognized as a 2026 AZBio Awards Fast Lane honoree, marking an important milestone in the company’s journey to advance cancer detection through innovative molecular diagnostic technology.
The recognition highlights the company’s achievements in translating university research into practical diagnostic innovation and reflects the growing impact of Arizona’s life sciences and biotechnology community.
A Prestigious Recognition at the 2026 AZBio Awards
The Arizona Bioindustry Organization (AZBio) recognizes organizations and individuals making meaningful contributions to Arizona’s bioscience industry through its annual AZBio Awards.
At the 2026 awards, Precision Epigenomics was named one of three recipients of the Fast Lane Award, which recognizes companies that have achieved outstanding milestones over the preceding 18 months.
This recognition celebrates the company’s progress in advancing cancer diagnostics and bringing its innovative technology closer to patients.
The achievement also highlights the University of Arizona’s continued contribution to bioscience innovation, demonstrating how academic research, entrepreneurship, and industry collaboration can help move scientific discoveries toward real-world applications.
Advancing Cancer Detection Through Innovative Technology
At the heart of Precision Epigenomics’ work is its commitment to advancing molecular diagnostics through epigenetics.
Building on research led by Mark Nelson, professor of pathology at the University of Arizona and CEO of Precision Epigenomics, the company has developed EPISEEK® Multi-Cancer Early Detection, an innovative blood-based test designed to detect more than 60 types of cancer.
The technology analyzes circulating tumor DNA (ctDNA), which is released by tumors into the bloodstream. It examines unique epigenetic modifications in this DNA to identify signals associated with different cancer types.
Using a simple blood draw, the EPISEEK® test offers a blood-based approach to multi-cancer detection.
The development of this technology represents an important step in translating scientific research into diagnostic solutions that can be used in clinical settings.
From University Research to Real-World Innovation
Precision Epigenomics’ recognition also reflects the importance of turning promising scientific discoveries into practical innovations.
The company’s technology builds on research conducted by experts associated with the University of Arizona College of Pharmacy, BIO5 Institute, and University of Arizona Cancer Center.
With business formation and development support from Tech Launch Arizona, the university’s commercialization arm, the company has continued advancing its technology and business development efforts.
Additional support from the Flinn BioEntrepreneurship program and a Small Business Innovation Research (SBIR) grant from the National Cancer Institute has helped support the company’s progress.
Today, EPISEEK® Multi-Cancer Early Detection is available and in use for patients, representing a significant milestone in the journey from academic research to commercial diagnostic innovation.
The Power of Teamwork and Collaboration
Behind every meaningful scientific advancement is a team of people working toward a shared vision.
Precision Epigenomics’ progress reflects the combined expertise and contributions of researchers, scientists, university partners, business development professionals, and supporters within Arizona’s growing bioscience ecosystem.
The collaboration between the University of Arizona’s research community and Tech Launch Arizona demonstrates how strong partnerships can help transform scientific discoveries into innovative technologies.
From research and development to commercialization and clinical application, every stage requires dedication, expertise, and teamwork.
The company’s 2026 AZBio Awards recognition is not simply a celebration of technological achievement. It is also a testament to the collective effort, commitment, and shared vision that continue to move Precision Epigenomics forward.
Looking Ahead: Continuing to Advance Cancer Diagnostics
Being named a 2026 AZBio Awards Fast Lane honoree is an important milestone for Precision Epigenomics, but it also represents the potential for continued innovation in cancer diagnostics.
As the company builds on its research foundation and advances its EPISEEK® technology, its work reflects the possibilities that emerge when scientific discovery meets entrepreneurial vision and collaborative effort.
Precision Epigenomics remains part of an exciting movement in biotechnology focused on advancing molecular diagnostics and exploring new approaches to multi-cancer early detection.
We are honored to be recognized alongside the innovators and leaders helping shape Arizona’s bioscience industry.
This achievement belongs to the entire team, our research collaborators, university partners, and everyone who has contributed to making this progress possible.
Together, we are moving science forward and helping shape the future of cancer diagnostics.